MedTrace Logo

Concurrent Chemoradiotherapy Containing Paclitaxel&Cisplatin With/Without Tarceva in Locally Advanced Esophageal Cancer

NCT00686114 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 344

Last updated 2014-04-29

No results posted yet for this study

Summary

This study is multi-center randomized phase III one to evaluate the difference in local-control and survival rate between patients receiving concurrent chemoradiotherapy combined Tarceva or not.

Conditions

  • Esophageal Cancer

Interventions

DRUG

Paclitaxel

135mg/m2, day 1 and day 29 of the radiotherapy.

DRUG

Cisplatin

20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.

DRUG

Tarceva

150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)

RADIATION

Radiotherapy

Enlarged field radiotherapy

RADIATION

Radiotherapy

Conventional field radiotherapy

Sponsors & Collaborators

  • Wenzhou Medical University

    lead OTHER

Principal Investigators

  • Shixiu Wu, MD · 1st affliated hospital of Wen Zhou Medical college

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00686114 on ClinicalTrials.gov